Safety and vasopressor effect of rosuvastatin in septic patients
El Gendy, H., Elsharnouby, N. (2014). Safety and vasopressor effect of rosuvastatin in septic patients. EKB Journal Management System, 30(3), 311-317. doi: 10.1016/j.egja.2014.02.005
Hanaa A. El Gendy; Noha M. Elsharnouby. "Safety and vasopressor effect of rosuvastatin in septic patients". EKB Journal Management System, 30, 3, 2014, 311-317. doi: 10.1016/j.egja.2014.02.005
El Gendy, H., Elsharnouby, N. (2014). 'Safety and vasopressor effect of rosuvastatin in septic patients', EKB Journal Management System, 30(3), pp. 311-317. doi: 10.1016/j.egja.2014.02.005
El Gendy, H., Elsharnouby, N. Safety and vasopressor effect of rosuvastatin in septic patients. EKB Journal Management System, 2014; 30(3): 311-317. doi: 10.1016/j.egja.2014.02.005

Safety and vasopressor effect of rosuvastatin in septic patients

Egyptian Journal of Anaesthesia
Volume 30, Issue 3, July 2014, Page 311-317  XML PDF (641.18 K)
DOI: 10.1016/j.egja.2014.02.005
View on SCiNiTO View on SCiNiTO
Authors
Hanaa A. El Gendy; Noha M. Elsharnouby
Abstract
Background
Statins anti-inflammatory and antioxidant properties improve vascular function in septic patients. The aim of this prospective study was to assess vasopressor effect and safety of rosuvastatin therapy in septic patient.
Methods
One hundred and eight patients admitted to intensive care unit (ICU) with suspected or confirmed infection plus at least 2 systemic inflammatory response syndrome criteria were included in this prospective double-blinded randomized two groups’ parallel study. Group R received standard therapy and rosuvastatin 20 mg/day and Group C received standard therapy with placebo/day for 14 days.
Results
The number of ABPSPD was significantly increased 11(3) vs. 8 (3) ( = 0.0001), with a shorter time to initial ABPSPD 18(21) vs. 41(37) h ( = 0.0001) in Group R than Group C. Norepinephrine dose 0.8 (0.5) vs. 1.6 (0.6) and duration 3(2) vs. 6(3) were significantly reduced in Group R with no significant elevation in transaminases or CPK.
Conclusions
Rosuvastatin 20 mg/day in septic patients increased number ABPSPD, decreased time to initial ABPSPD, norepinephrine dose and duration, with no significant elevation in transaminases or CPK.
Statistics
Article View: 17
PDF Download: 14